There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib(Drug information on bortezomib) into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.
“As is 100% of the time true, as far as I know, the adverse cytogenetics— del(13) and t(4;14)—are no longer relevant in the context of bortezomib- containing initial therapies.” The rate of complete or near-complete response increased from 39% to 46% to 72%, going from the intent-to-treat population to patients who completed treatment to transplant recipients, Dr. Anderson observed, characterizing the rates achieved as “truly remarkable.”
“I believe this is another example of a very active bortezomib-containing new therapy,” he said.
The main article can be found here:
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma